CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.56
+0.08%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.34
From 52W high−50.78%
Volume4.46M
Market cap$1.06B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$12.34
From 52W high
−50.78%
Volume
4.46M
Market cap
$1.06B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.4x
P/E (TTM)
—
RSI (14)
35.4
MomentumView details →
1D Return
+0.08%
YTD Return
+61.56%
SummaryUpdated Jun 1, 2026
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Burlingame, California. The company went public in March 2016 and focuses on developing novel immuno-oncology and immunology therapies. Corvus specializes in targeting specific pathways that regulate immune system function, with particular expertise in developing small molecule inhibitors and monoclonal antibodies for cancer and autoimmune diseases.
Similar companies
Latest newsMore news →
Corvus Pharmaceuticals announced the publication in Blood of final Phase 1 data from its soquelitinib Phase 1/1b T cell lymphoma trial, supporting ongoing registration trials.24d agoCorvus Pharmaceuticals reported a net loss of $18.0 million for Q2 2026, compared to a net loss of $8.0 million in Q2 2025, with diluted EPS of -$0.19.46d ago